by Brendon Nafziger
, DOTmed News Associate Editor | March 14, 2012
European regulators have cleared Mevion Medical Systems' small-footprint proton therapy system for sale in the European Union.
Littleton, Mass.-based Mevion, formerly Still River Systems
, said Wednesday it received CE Marking for its Mevion S250, a superconducting synchrocyclotron used in high-tech cancer treatments.
"We are very pleased to receive CE Marking certification for the Mevion S250, the final step to offer this first of its kind proton therapy system to health care providers and patients in the European Union," Mevion's CEO Joseph K. Jachinowski said in a statement.
The device can fire protons at energies up to 250 MeV to blast cancers, but it has a more compact design, and potentially lower cost, than other systems on the market. The Mevion S250 is still pending Food and Drug Administration clearance.
Mevion said it's installing three systems in the U.S. The first installation, at a Barnes Jewish Hospital cancer center in St. Louis, began in October. That device is already producing a 250 MeV beam, Mevion said. The two other installations already underway are at Robert Wood Johnson University Hospital in New Brunswick, N.J. and Oklahoma University in Oklahoma City. Mevion said they should be completed this year.
But Mevion seems to have more orders on the way. A Florida radiation oncology group announced in January
it would begin installing a Mevion S250 at a proton therapy site it's building in 2013.